| Literature DB >> 27999591 |
Bülent Ödemiş1, Ufuk Barış Kuzu1, Erkin Öztaş1, Fatih Saygılı1, Nuretdin Suna1, Orhan Coskun1, Adem Aksoy1, Zeliha Sırtaş1, Derya Arı1, Yener Akpınar1.
Abstract
Background. Most common bile duct (CBD) stones can be removed with standard techniques using endoscopic retrograde cholangiopancreatography (ERCP), but in some cases additional methods are needed. In this study we aimed to investigate the management of patients with difficult stones and the factors that affect the outcome of patients that have undergone periodic endobiliary stenting. Materials and Methods. Data of 1529 patients with naive papilla who had undergone ERCP with an indication of CBD stones was evaluated retrospectively. Stones that could not be removed with standard techniques were defined as "difficult stones." Cholangiograms of patients who had difficult stones were revised prospectively. Results. Two hundred and eight patients (13.6%) had difficult stones; 150 of these patients were followed up with periodic endobiliary stenting and successful biliary clearance was achieved in 85.3% of them. Both CBD (p < 0.001) and largest stone size (p < 0.001) were observed to be significantly reduced between the first and the last procedure. This difference was even more significant in successfully treated patients. Conclusions. Periodic endobiliary stenting can be used as an effective treatment for patients with difficult stones. Sizes of the CBD and of the largest stone are independent risk factors that affect the success rate.Entities:
Year: 2016 PMID: 27999591 PMCID: PMC5143714 DOI: 10.1155/2016/8749583
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Design of the study population (ESWL: extracorporeal shock wave lithotripsy).
Main differences between patients with easy and difficult stones.
| Variable | Easy stone ( | Difficult stone ( |
|
|---|---|---|---|
| Age (year) | 62.9 ± 17 | 66 ± 16.9 | 0.015 |
| Gender: women/men; | 811 (61.4)/510 (38.6) | 136 (65.4)/72 (34.6) | 0.267 |
| Laboratory findings | |||
| Glucose (mg/dL) | 115 ± 45.1 | 115.6 ± 60.3 | 0.915 |
| ALT (U/L) | 80 (5−2665) | 48 (1−643) | <0.001 |
| AST (U/L) | 59 (2−1851) | 47 (10−607) | 0.004 |
| GGT (U/L) | 278 (6−2400) | 215 (4−5811) | 0.016 |
| ALP(U/L) | 183 (9−2069) | 200 (16−2105) | 0.418 |
| Amylase (mg/dL) | 208 ± 551 | 114.4 ± 158.9 | 0.954 |
| Total bilirubin (mg/dL) | 5.3 ± 4.58 | 9.6 ± 11.8 | 0.006 |
| Endoscopic/radiological findings; | |||
| Cholecystectomized patients | 318 (%25.6) | 78 (41.9) | <0.001 |
| Papilla in bulbus | 16 (1.2) | 7 (3.5) | 0.025 |
| Papilla in 3rd portion | 11 (0.8) | 7 (3.5) | 0.006 |
| Periampullary diverticula | 236 (17.9) | 29 (13.9) | 0.063 |
| History of gastric operation | 14 (1.1) | 4 (1.9) | 0.100 |
| Impacted stone | 2 (0.15) | 18 (8.6) | <0.001 |
| Stricture distal to the stone | 3 (0.22) | 40 (13.6) | <0.001 |
| Number of patients with dilated CBD; | 743 (70.4) | 114 (94.2) | <0.001 |
Values are presented as number (%), mean ± SD, or median (range).
ALT: alanine aminotransferase; AST: aspartate aminotransferase; CBD: common bile duct; GGT: gamma glutamyl transferase; ALP: alkaline phosphatase.
Comparison of groups that underwent periodic endobiliary stenting.
| Variable | Successful ( | Unsuccessful ( |
|
|---|---|---|---|
| Age (year) | 67.8 ± 17.4 | 61 ± 15.2 | 0.052 |
| Gender: women/men; | 99 (77.3)/29 (22.7) | 19 (86.4)/3 (13.6) | 0.340 |
| Glucose (mg/dL) | 114 ± 34.2 | 111 ± 37.9 | 0.314 |
| Laboratory findings | |||
| ALT (U/L) | 72.9 ± 70.7 | 53.4 ± 62.4 | 0.082 |
| AST (U/L) | 70.9 ± 76.5 | 48.7 ± 36.3 | 0.416 |
| GGT (U/L) | 334 ± 568 | 265 ± 329 | 0.329 |
| ALP (U/L) | 276 ± 289 | 364 ± 326 | 0.297 |
| Amylase (mg/dL) | 128 ± 187 | 82 ± 41 | 0.888 |
| Total bilirubin (mg/dL) | 3.47 ± 6.8 | 2.7 ± 4.8 | 0.289 |
| Endoscopic/radiological findings | |||
| Cholecystectomized patients | 47 (36.7) | 11 (39.2) | 0.473 |
| Papilla in bulbus | 7 (5.5) | 0 | 0.559 |
| Papilla in 3rd portion | 4 (3.1) | 3 (13.6) | 0.060 |
| Periampullary diverticula | 19 (14.8) | 1 (%4.5) | 0.308 |
| History of gastric operation | 5 (3.9) | 0 | 0.446 |
| Impacted stone | 14 (%10.9) | 3 (%13.6) | 0.375 |
| Stricture distal to the stone | 27 (%21) | 6 (%27.2) | 0.379 |
| Number of ERCP sessions | 3.34 ± 1.57 (1–10) | 3.36 ± 2 (1–9) | 0.558 |
| Total follow-up (months) | 5 ± 7.5 (0.75–39.75) | 5.1 ± 7.5 (1–61) | 0.780 |
| Bile duct size in first session (mm) | 14.8 ± 3.8 (7–26) | 20.7 ± 7.3 (11–33) | 0.006 |
| Bile duct size in last session (mm) | 13.1 ± 3.68 (7–25) | 19.3 ± 7 (11–29) | <0.001 |
| Number of patients with reduced CBD diameter | 106 (82.8) | 7 (31.8) | 0.001 |
| Number of patients with more than 3 stones at initial session; | 75 (58.5) | 13 (46.4) | 0.931 |
| Maximum stone size in first session (mm) | 15.8 ± 5.5 (12–30) | 27.7 ± 10.3 (24–44) | <0.001 |
| Maximum stone size in last session (mm) | 13.3 ± 4.1 (6–24) | 26.1 ± 7.5 (22–41) | <0.001 |
| Number of patients with reduced diameter of the largest stone; | 97 (75.7) | 16 (57.1) | 0.413 |
| Additional technique; | |||
| Mechanical lithotripsy | 25 (19.5) | 2 (7.1) | 0.252 |
| Balloon sphincteroplasty | 6 (4.6) | 1 (3.5) | 0.591 |
Values are presented as number (%), mean ± SD, or median (range).
ALT: alanine aminotransferase; AST: aspartate aminotransferase; CBD: common bile duct; ERCP: endoscopic retrograde cholangiopancreatography; GGT: gamma glutamyl transferase; ALP: alkaline phosphatase.
Multivariate analysis for factors affecting endoscopic success.
| Variable | OR | %95 CI |
|
|---|---|---|---|
| Age | 0.963 | (0.921–1.006) | 0.089 |
| Previous cholecystectomy | 1.006 | (0.997–1.015) | 0.181 |
| Periampullary diverticula | 1.040 | (0.315–1.780) | 0.774 |
| Bile duct size in first session | 0.780 | (0.681–0.893) | 0.001 |
| Maximum stone size in first session | 0.808 | (0.726–0.898) | 0.001 |
Published cases of papillary balloon dilation, mechanical lithotripsy, and laser lithotripsy for difficult bile duct stones.
| Ref. | Treatment | Total number of patients | Stone size (mm) | Success rate (%) |
|---|---|---|---|---|
| Schneider et al. [ | ML | 209 | 4–80 | 87.6 |
| Hintze et al. [ | ML | 84 | >15 | 98.4 |
| Garg et al. [ | ML | 87 | >15 | 79.0 |
| Cipolletta et al. [ | ML | 162 | 9–50 | 84 |
| Rosa et al. [ | ESPBD | 68 | 12–30 | 95.6 |
| Stefanidis et al. [ | ESPBD | 45 | 12–20 | 97.7 |
| Minami et al. [ | ESPBD | 88 | >12 | 99 |
| Bang et al. [ | ESPBD | 22 | 5–25 | 72.7 |
| Sauer et al. [ | LL | 20 | 11–35 | 90 |
| Hochberger et al. [ | LL | 60 | >10 | 87 |
| Lee et al. [ | LL | 10 | 16–23 | 90 |
| Maydeo et al. [ | LL | 60 | 15–25 | 100 |
ML: mechanical lithotripsy; ESLBD: endoscopic sphincterotomy and papillary balloon dilation; LL: laser lithotripsy.